23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound . In Vitro 23-epi-26-Deoxyactein (DA :10 μM and 20 μM) inhibits 3T3-L1 adipogenesis through down-regulating the expression of C/ebpα , C/ebpβ , and Pparγ , which are the critical adipogenic transcription factors. 23-epi-26-Deoxyactein (DA) promotes mitochondrial biogenesis in pancreatic β-cells preventing methylglyoxal-induced oxidative cell damage and protects osteoblasts against Antimycin A-induced cell damage. 23-epi-26-Deoxyactein (DA) inhibits growth of the MCF7 human breast cancer cells and induces cell cycle arrest at G1 (IC 50 of 21μM). 23-epi-26-Deoxyactein (0.1-1 μM) protects osteoblasts against Antimycin A-induced cell damage . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Differentiation AssayCell Line: 3T3-L1 preadipocytes. Concentration: 0-50 μM. Incubation Time: 8 days. Result: 10 μM DA inhibited the adipogenesis of 3T3-L1 preadipocytes mainly at the early stage of differentiation. In Vivo 23-epi-26-Deoxyactein (DA: 5 and 10 mg/kg/d) significantly lowers body weight gain, fat mass, and liver weight in HFD-fed mice. 23-epi-26-Deoxyactein (DA) also reduces insulin resistance and serum lipoprotein levels in HFD-fed mice . 23-epi-26-Deoxyactein (DA) promotes adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Diet induced obesity in C57BL/6 mice . Dosage: 1-10 mg/kg. Administration: Orally, daily for 12 weeks. Result: Lowered body weight gain, fat mass, and liver weight. 5 mg/kg/d DA significantly improved HFD-induced glucose intolerance. Form:Solid